Panel discussion


Date:April 22, 2024
Room:Marriott Hotel

Panel title

Maintaining funding flexibility to grow value

Panel summary

Capital markets are opening up in 2024 for biotech after two dry years, and a few Swiss companies are considering public listing. Is it the best way to grow value? What paths can a late-stage biotech consider? Join us to discuss the opportunities and challenges an IPO brings, and exchange experience in the Swiss Biotech ecosystem.

Speaker information


Peter Mozerov, PhD, Senior Manager, KPMG AG


Reto Näf, Chairman of the BoD, Topadur Pharma AG
Dario Eklund, CEO, Santhera Pharmaceuticals Holding AG
Sascha Bucher, Co-Founder and Partner, Forty51 Ventures
Valentin Piëch, PhD, Managing Partner, Biomed VC AG

Company profile

Making a positive impact on the world and delivering on our fundamental promise of quality. At KPMG we understand the role we play in the wider society. As a leading professional services firm, we are here to support our clients and stakeholders and provide trust in the market. Our purpose to inspire confidence and empower change, to create a better future for our clients, people and society has never been more relevant.

Further information

Follow us